Ignite Creation Date:
2024-05-05 @ 11:46 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00123851
Status:
COMPLETED
Last Update Posted:
2009-04-28
First Post:
2005-07-25
Brief Title:
Tarceva Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Study Overview
Official Title:
A Phase II Study of OSI-774 Tarceva in Combination With Oxaliplatin and Capecitabine in Previously Treated Patients With Stage IV Colorectal Cancer
Status:
COMPLETED
Status Verified Date:
2009-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is designed to investigate the safety tolerability and the effectiveness when OSI-774 tarceva is combined with oxaliplatin and capecitabine in treating patients with metastatic colorectal cancer
Detailed Description:
Patients will be treated with OSI-774 orally daily oxaliplatin intravenously every 3 weeks and capecitabine orally twice daily for 14 days followed by a 7-day rest period This will constitute a 21-day treatment cycle Treatment will continue until disease progression or unacceptable toxicity occurs
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None